MDT Jan 2026 80.000 call
| Previous Close | 13.40 |
| Open | 13.30 |
| Bid | 13.15 |
| Ask | 13.75 |
| Strike | 80.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 13.30 - 13.40 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 579 |
PR NewswireMedtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter, an all-in-one pulsed field (PF) and radiofrequency (RF) ablation and high density (HD) mapping catheter for the treatment of persistent atrial fibrillation (AFib). The SPHERE Per-AF study, a U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) pivotal trial, c
CNW GroupLate-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure™
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its primary safety and effectiveness endpoints, exceeding prespecified performance goals, in the global Lead Evaluation for Defibrillation and Reliability (LEADR) Pivotal Trial. Late breaking results were presented at Heart Rhythm 2024 and simultaneously published in the journal Heart Rhythm. Worldwide, the OmniaSecure defibrillation lead is investigational
ZacksInvestors Heavily Search Medtronic PLC (MDT): Here is What You Need to Know
Medtronic (MDT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
